Kathryn Guarini exercised Options for 400 Regeneron shares at $719.37 per share on Sept. 2, 2026. After the related transactions, her reported holdings were 603 shares and 1,158 derivative securities, giving investors the stated post-transaction ownership figures for both categories.
Key Highlights
- Kathryn Guarini sold 400 Regeneron shares at $850 per share.
- Her reported share ownership after the sale was 603 shares.
- Guarini owned 1,158 derivative securities after the option exercise.
REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) director Kathryn Guarini exercised options for 400 shares at $719.37 per share on Sept. 2, 2026. The transaction left Guarini with 1,003 shares.
Option Exercise
and $850 Share Sale Guarini also exercised options covering 400 derivative securities on Sept. 2, 2026. Her derivative-securities holdings stood at 1,158 after that transaction. A separate transaction involved the sale of 400 shares at $850 per share. Guarini’s reported share ownership following the sale was 603 shares. The option exercises carried transaction code M, while the share sale carried transaction code S.
Separate Ownership Positions Reported The
reported holdings distinguish between shares and derivative securities. Guarini held 603 shares after the sale and 1,158 derivative securities after the exercise. The source records the exercise price as $719.37 per share and the sale price as $850 per share. Both transactions took place on Sept. 2, 2026.
FAQs
Q: How many Regeneron shares did Kathryn Guarini exercise?
A: Kathryn Guarini exercised options for 400 Regeneron shares at $719.37 per share on Sept. 2, 2026. She then held 1,003 shares.
Q: What was the price of Kathryn Guarini’s Regeneron share sale?
A: Guarini sold 400 Regeneron shares at $850 per share on Sept. 2, 2026. The filing reports that her share ownership after the transaction was 603 shares.
Q: How many derivative securities did Kathryn Guarini own afterward?
A: After the option exercise, Guarini owned 1,158 derivative securities. Her separate reported share ownership after the sale was 603 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.